Abeona Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Abeona Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-34.4%
Buyback Yield
| Total Shareholder Yield | -34.4% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Health Check: How Prudently Does Abeona Therapeutics (NASDAQ:ABEO) Use Debt?
Jan 15
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?
Sep 23We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
May 01We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
Jan 04Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation
Aug 16Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?
Mar 31Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value
Oct 19Abeona Therapeutics stock continues recent strong run, shares rise ~10%
Oct 04Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M
Aug 11Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement
Jul 20Abeona crashes 21% as reverse stock split takes effect
Jul 05Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely
Mar 02Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Aug 17Abeona Therapeutics shares rise after letter to stockholders
May 26Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt
Apr 28Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)
Feb 21How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 19What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?
Dec 15
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ABEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABEO's dividend payments have been increasing.
Dividend Yield vs Market
| Abeona Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ABEO) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 1.7% |
| Analyst forecast (ABEO) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ABEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ABEO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABEO has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 09:55 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abeona Therapeutics Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Elemer Piros | Cantor Fitzgerald & Co. |